Overall verdict
Buy
8.3/10
1-year performance
-6.88%
Score breakdown
Down 6.9% over 1 year, 39% of the 52-week range.
5 analysts, target +1.3% vs the price.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases ;
and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Mary Szela
Founded
2020
Employees
102
Revenue / employee
442 657 USD
Next earnings
November 12, 2026 (estimated)
Institutional holders
- First Light Asset Management, LLC10.64%
- BlackRock, Inc.4.32%
- Cerity Partners LLC3.95%
- VANGUARD CAPITAL MANAGEMENT LLC2.81%
- GEODE CAPITAL MANAGEMENT, LLC1.93%
- Nantahala Capital Management, LLC1.62%
- GILDER GAGNON HOWE & CO LLC1.38%
- STATE STREET CORP0.99%
- WHITE PINE CAPITAL LLC0.89%
- Other institutions8.42%
- Rest of the register63.05%
82 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
7.95 USD
52-week low
2.20 USD
1-year performance
-6.88%
Declining
Year-to-date performance
-35.78%
Declining
Drawdown
-43.77%
Major drawdown
Position in the 52-week range
39% of range
Gross margin 85.8%, the company loses 62.6% of its revenue, ROIC -102.9%, ROE 438.3%.
Net margin
-62.59%
Negative
Sector -229.34%|S&P 12.97%
Gross margin
85.79%
Exceptional
Return on equity (ROE)
438.31%
Exceptional
Sector -58.12%|S&P 16.52%
Return on invested capital (ROIC)
-102.87%
Negative
Free cash flow margin (FCF)
-53.01%
Negative
Revenue to net income
Growth
3.6/10Revenue up 1.7% over 1 year.
Revenue (trailing 12 months)
45.1M USD
Revenue growth (1y)
1.73%
Moderate
Revenue growth (3y)
264.18%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.76|S&P 0.86
P/E vs its own 5-year history
among the 8% highest valuations
At its historical high
Market cap
275M USD
Financial strength
5.8/10Cash covers 134.5% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-181.10%
Net cash
Cash
46.3M USD
Cash / market cap
16.82%
Very solid
Cash / total debt
134.46%
Net cash
Interest coverage
-5.2x
Stretched
Net debt
-11.9M USD
Equity
6.5M USD
Closed daily candles, 23 months
Last close on September 4, 2026: 5.00 USD
- MM205.23
- MM504.74
- MM2004.84
- RSI 1450.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.21%
200-day average slope, 3 months
-1.35%
50-day average slope, 1 month
+16.26%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.58 % per day
Volatility change
-49.08%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.33 (5) | -0.45 | 53 (5) | -18 (2) | -19 (5) |
| 2027 | -0.26 (5) | -0.25 | 75 (5) | -6 (2) | -16 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MTAC | 8.3 | N/A | 275M USD | Not meaningful (loss) | -62.6 % | 1.7 % | -102.9 % | — | -8.7 % | -6.9 % | ||
| 2 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 3 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 4 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 5 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 6 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 7 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 8 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 9 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % |
